tailieunhanh - Health-related quality of life scores of metastatic pancreatic cancer patients responsive to frst line chemotherapy compared to newly derived EORTC QLQ-C30 reference values

Metastatic pancreatic cancer (mPC) and its treatments signifcantly impact health-related quality of life (HRQoL). POLO, a randomized, double-blind, placebo-controlled phase 3 trial evaluated the efcacy of olaparib as maintenance therapy in germline BRCA mutated mPC patients who had not progressed during ≥16weeks of frst-line platinum-based chemotherapy. HRQoL was assessed using the EORTC QLQ-C30. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN